❌

Reading view

"When to Hand Off, When to Work Together": Expanding Human-Agent Co-Creative Collaboration through Concurrent Interaction

arXiv:2603.02050v4 Announce Type: replace-cross Abstract: As agents move into shared workspaces and their execution becomes visible, human-agent collaboration faces a fundamental shift from sequential delegation to concurrent co-creation. This raises a new coordination problem: what interaction patterns emerge, and what agent capabilities are required to support them? Study 1 (N=10) revealed that process visibility naturally prompted concurrent intervention, but exposed a critical capability gap: agents lacked the collaborative context awareness needed to distinguish user feedback from independent parallel work. This motivated CLEO, a design probe that embodies this capability, interpreting concurrent user actions as feedback or independent work and adapting execution accordingly. Study 2 (N=10) analyzed 214 turn-level interactions, identifying a taxonomy of five action patterns and ten codes, along with six triggers and four enabling factors explaining when and why users shift between collaboration modes. Concurrent interaction appeared in 31.8% of turns. We present a decision model, design implications, and an annotated dataset, positioning concurrent interaction as what makes delegation work better.
  •  

Molecular and Phenotypic Characterization of Fluid-Derived Patient-Derived Cell and Organoid Models in Advanced Gastric Cancer

J Gastric Cancer. 2026 Apr;26(2):260-278. doi: 10.5230/jgc.2026.26.e19.

ABSTRACT

PURPOSE: Patient-derived cells (PDCs) and patient-derived organoids (PDOs) are complementary preclinical models widely used in translational cancer research. However, their molecular and functional differences have not been systematically characterized. This study established and analyzed paired PDC and PDO models derived from the same gastric cancer ascites to delineate platform-dependent molecular and functional profiles.

MATERIALS AND METHODS: Malignant ascites or pleural fluid obtained from 6 patients with advanced gastric cancer were used to establish paired PDC and PDO models. All pairs underwent comprehensive multi-omics profiling, integrating genomic, transcriptomic, and proteomic data. Phenotypic characterization included morphological, histological, proliferative, and cell cycle analyses. Drug sensitivity assays were performed using 4 chemotherapeutic agents commonly used to treat gastric cancer.

RESULTS: The 6 paired PDC and PDO models exhibited distinct morphological characteristics. Whole-genome analyses demonstrated high concordance among primary tumors, PDCs, and PDOs, confirming tumor representation across platforms. Multi-omics profiling identified platform-dependent molecular signatures; PDOs were enriched for extracellular matrix remodeling and stemness, whereas PDCs displayed proliferation- and immune-related signatures. Clinically relevant biomarkers, including HER2 and MET alterations, were concordant with primary tumors. Notably, drug responses differed between platforms and patients, indicating platform-dependent and patient-specific chemosensitivity.

CONCLUSIONS: Paired PDC and PDO models derived from the same patients preserved core patient-specific tumor characteristics while exhibiting distinct molecular and functional profiles. These findings underscore the culture platform as a critical determinant of experimental outcomes and therapeutic responses. Therefore, careful selection of an appropriate preclinical model is essential to accurately address biological questions and optimize precision oncology strategies.

PMID:41942359 | DOI:10.5230/jgc.2026.26.e19

  •  

Molecular and Phenotypic Characterization of Fluid-Derived Patient-Derived Cell and Organoid Models in Advanced Gastric Cancer

J Gastric Cancer. 2026 Apr;26(2):260-278. doi: 10.5230/jgc.2026.26.e19.

ABSTRACT

PURPOSE: Patient-derived cells (PDCs) and patient-derived organoids (PDOs) are complementary preclinical models widely used in translational cancer research. However, their molecular and functional differences have not been systematically characterized. This study established and analyzed paired PDC and PDO models derived from the same gastric cancer ascites to delineate platform-dependent molecular and functional profiles.

MATERIALS AND METHODS: Malignant ascites or pleural fluid obtained from 6 patients with advanced gastric cancer were used to establish paired PDC and PDO models. All pairs underwent comprehensive multi-omics profiling, integrating genomic, transcriptomic, and proteomic data. Phenotypic characterization included morphological, histological, proliferative, and cell cycle analyses. Drug sensitivity assays were performed using 4 chemotherapeutic agents commonly used to treat gastric cancer.

RESULTS: The 6 paired PDC and PDO models exhibited distinct morphological characteristics. Whole-genome analyses demonstrated high concordance among primary tumors, PDCs, and PDOs, confirming tumor representation across platforms. Multi-omics profiling identified platform-dependent molecular signatures; PDOs were enriched for extracellular matrix remodeling and stemness, whereas PDCs displayed proliferation- and immune-related signatures. Clinically relevant biomarkers, including HER2 and MET alterations, were concordant with primary tumors. Notably, drug responses differed between platforms and patients, indicating platform-dependent and patient-specific chemosensitivity.

CONCLUSIONS: Paired PDC and PDO models derived from the same patients preserved core patient-specific tumor characteristics while exhibiting distinct molecular and functional profiles. These findings underscore the culture platform as a critical determinant of experimental outcomes and therapeutic responses. Therefore, careful selection of an appropriate preclinical model is essential to accurately address biological questions and optimize precision oncology strategies.

PMID:41942359 | PMC:PMC13053824 | DOI:10.5230/jgc.2026.26.e19

  •  
❌